Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Novel second-line treatments are needed for patients with advanced urothelial cancer (UC). Interim analysis of the phase III KEYNOTE-045 study showed a superior overall survival (OS) benefit of pembrolizumab, a programmed death 1 inhibitor, versus chemotherapy in patients with advanced UC that progressed on platinum-based chemotherapy. Here we report the long-term safety and efficacy outcomes of KEYNOTE-045. PATIENTS AND METHODS: Adult patients with histologically/cytologically confirmed UC whose disease progressed after first-line, platinum-containing chemotherapy were enrolled. Patients were randomly assigned 1 : 1 to receive pembrolizumab [200 mg every 3 weeks (Q3W)] or investigator's choice of paclitaxel (175 mg/m2 Q3W), docetaxel (75 mg/m2 Q3W), or vinflunine (320 mg/m2 Q3W). Primary end points were OS and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) by blinded independent central radiology review (BICR). A key secondary end point was objective response rate per RECIST v1.1 by BICR. RESULTS: A total of 542 patients were enrolled (pembrolizumab, n = 270; chemotherapy, n = 272). Median follow-up as of 26 October 2017 was 27.7 months. Median 1- and 2-year OS rates were higher with pembrolizumab (44.2% and 26.9%, respectively) than chemotherapy (29.8% and 14.3%, respectively). PFS rates did not differ between treatment arms; however, 1- and 2-year PFS rates were higher with pembrolizumab. The objective response rate was also higher with pembrolizumab (21.1% versus 11.0%). Median duration of response to pembrolizumab was not reached (range 1.6+ to 30.0+ months) versus chemotherapy (4.4 months; range 1.4+ to 29.9+ months). Pembrolizumab had lower rates of any grade (62.0% versus 90.6%) and grade ≥3 (16.5% versus 50.2%) treatment-related adverse events than chemotherapy. CONCLUSIONS: Long-term results (>2 years' follow-up) were consistent with those of previously reported analyses, demonstrating continued clinical benefit of pembrolizumab over chemotherapy for efficacy and safety for treatment of locally advanced/metastatic, platinum-refractory UC. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02256436.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“1) [7] and an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0, 1, or 2.”
BackgroundThe National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · cited 7×
“gov, NCT02256436) is an ongoing, international, randomized, activecontrolled, phase III trial of second-line pembrolizumab versus investigator’s choice of docetaxel, paclitaxel, or vinflunine in patients with recurrent advanced UC that has progressed with platinum-based chemotherapy [3].”
BackgroundResultSelf-citationSeiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“Phase I studies with the PD-1 inhibitor pembrolizumab showed clinical antitumor activity in several solid tumor types, including previously treated urothelial cancer (UC) [1, 2].”
BackgroundSharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Self-citationProstate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
Alfred Witjes, J., Lebret, T., Compérat, E. M., Cowan, N. C., De Santis, M., Bruins, H. M., Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.020 · Cited by 1,476
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Self-citationAcquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869 · cited 1×
“PD-L1 expression seemed to predict a greater response to nivolumab and to durvalumab in single-arm phase I/II studies [16, 17].”
BackgroundSelf-citationSharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Plimack, E. R., Bellmunt, J., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J., Lunceford, J., Saraf, S., Perini, R. F., & O'Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 335
Self-citationBladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Bellmunt, J., Orsola, A., Leow, J. J., Wiegel, T., De Santis, M., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu223 · Cited by 335
Self-citationSun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
Vaughn, D. J., Joaquim Bellmunt, B., Fradet, Y., Lee, J., Fong, L. H., Vogelzang, N. J., Climent, M. Á., Petrylak, D. P., Choueiri, T. K., Necchi, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9562 · Cited by 122
Self-citationPetrylak, D. P., Powles, T., Bellmunt, J., Braiteh, F., Loriot, Y., Morales-Barrera, R., Burris, H. A., Kim, J. W., Ding, B., Kaiser, C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5440 · Cited by 120
Self-citationOptimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives
Leow, J. J. J., Liu, Z., Tan, T. W., Lee, Y. M., Yeo, E. K. S., & Chong, Y.-L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s225301 · Cited by 74
Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer
Sarfaty, M., Hall, P. S., Chan, K., Virik, K., Leshno, M., Gordon, N., Moore, A., Neiman, V., Rosenbaum, E., & Goldstein, D. A. (2018) · European Urology · doi:10.1016/j.eururo.2018.03.006 · Cited by 65
Resch, I., Shariat, S. F., & Gust, K. M. (2018) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-018-0396-y · Cited by 32
The Role of Immunotherapy in Urologic Cancers.
May, A. M., Roustio, L., & Hamilton, Z. A. (2020) · PubMed · Cited by 9
Cited by
Witjes, J. A., Bruins, H. M., Cathomas, R., Compérat, E. M., Cowan, N. C., Gakis, G., Hernández, V., Linares Espinós, E., Lorch, A., Neuzillet, Y., et al. (2021) · European Urology · doi:10.1016/j.eururo.2020.03.055 · Cited by 2,017
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Powles, T., Park, S. H., Voog, E., Caserta, C., Valderrama, B. P., Gurney, H., Kalofonos, H., Radulović, S., Demey, W., Ullén, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002788 · Cited by 1,493
Self-citationEnfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Self-citationAcquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Metadata
- Authors
- Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., Gerritsen, W., Gurney, H., Quinn, D. I., Culine, S., Sternberg, C. N., Nam, K., Frenkl, T. L., Perini, R. F., de Wit, R., & Bajorin, D. F.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 30
- Issue
- 6
- Pages
- 970-976
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2943108118
- Cited by
- 480
- References
- 20
- FWCI
- 55.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.